Summary
Global Markets Direct’s, ‘Community Acquired Pneumonia - Pipeline Review, H2 2016’, provides an overview of the Community Acquired Pneumonia pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Community Acquired Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Community Acquired Pneumonia and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Community Acquired Pneumonia
- The report reviews pipeline therapeutics for Community Acquired Pneumonia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Community Acquired Pneumonia therapeutics and enlists all their major and minor projects
- The report assesses Community Acquired Pneumonia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Community Acquired Pneumonia
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Community Acquired Pneumonia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Community Acquired Pneumonia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Aridis Pharmaceuticals LLC
BioAegis Therapeutics, Inc.
Biotest AG
C10 Pharma AS
InflaRx GmbH
ioGenetics, Inc.
Kyorin Pharmaceutical Co., Ltd.
Lascco SA
Melinta Therapeutics, Inc
Merck & Co., Inc.
Nabriva Therapeutics AG
Paratek Pharmaceuticals, Inc.
TaiGen Biotechnology Co., Ltd.
Takeda Pharmaceutical Company Limited
Tetraphase Pharmaceuticals Inc.
TiGenix NV
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Community Acquired Pneumonia Overview 9
Therapeutics Development 10
Pipeline Products for Community Acquired Pneumonia - Overview 10
Community Acquired Pneumonia - Therapeutics under Development by Companies 11
Community Acquired Pneumonia - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Community Acquired Pneumonia - Products under Development by Companies 15
Community Acquired Pneumonia - Companies Involved in Therapeutics Development 17
Aridis Pharmaceuticals LLC 17
BioAegis Therapeutics, Inc. 18
Biotest AG 19
C10 Pharma AS 20
InflaRx GmbH 21
ioGenetics, Inc. 22
Kyorin Pharmaceutical Co., Ltd. 23
Lascco SA 24
Melinta Therapeutics, Inc 25
Merck & Co., Inc. 26
Nabriva Therapeutics AG 27
Paratek Pharmaceuticals, Inc. 28
TaiGen Biotechnology Co., Ltd. 29
Takeda Pharmaceutical Company Limited 30
Tetraphase Pharmaceuticals Inc. 31
TiGenix NV 32
Community Acquired Pneumonia - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Target 34
Assessment by Mechanism of Action 36
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
BT-086 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
C-10 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
CAL-02 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
ceftaroline fosamil - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Cx-611 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
DBAF-301 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
delafloxacin - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
IFX-1 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
KRPAM-1977X - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
KRPAM-1977Y - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
lefamulin acetate - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
nemonoxacin - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
omadacycline tosylate - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
PneumoMab - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
radezolid - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
Recombinant Plasma Gelsolin Replacement for Community Acquired Pneumonia - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
solithromycin - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
tosatoxumab - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
TP-271 - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
Community Acquired Pneumonia - Dormant Projects 97
Community Acquired Pneumonia - Discontinued Products 98
Community Acquired Pneumonia - Product Development Milestones 99
Featured News & Press Releases 99
Jun 28, 2016: Cempra Submits Marketing Authorization Application to EMA for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia 99
Jun 20, 2016: Nabriva Presents Data on Lefamulin at the American Society of Microbiology Microbe 2016 Conference 99
Jun 16, 2016: Cempra to Host Analyst and Investor Day on June 23, 2016 100
Jun 14, 2016: Melinta Therapeutics Presenting Results From Baxdela Programs At ASM Microbe 2016 Meeting 100
Jun 13, 2016: TaiGen Biotechnology Receives Market Approval from the China Food and Drug Administration for Taigexyn (nemonoxacin) 101
Jun 10, 2016: Cempra Announces Solithromycin Presentations at ASM Microbe 2016 Conference 101
May 31, 2016: Allergan Receives FDA Approval of TEFLARO (ceftaroline fosamil) for Pediatric Patients 102
May 25, 2016: Cempra Announces Successful Results in the Phase 2 Community Acquired Bacterial Pneumonia (CABP) Trial Conducted by Japanese Partner, Toyama Chemical (a subsidiary of FUJIFILM Holdings Corporation) 103
May 16, 2016: Nabriva Announces Lefamulin Presentation at ASM Microbe 2016 Conference 104
May 12, 2016: Cempra to Present Solithromycin IV Data at ATS 2016 105
May 01, 2016: Cempra Completes NDA Submissions for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia 105
Apr 11, 2016: Nabriva Initiates Second Phase 3 Clinical Trial of Lefamulin (“LEAP 2”) in Patients with Community-Acquired Bacterial Pneumonia 106
Apr 04, 2016: Cempra to Present Data on Solithromycin at ECCMID 107
Feb 24, 2016: Aridis Pharmaceuticals Expands Patent Portfolio for Several Fully Human Monoclonal Antibodies Against Infectious Disease Targets 107
Feb 05, 2016: The Lancet Infectious Diseases Publishes Positive Phase 3 Study Results for Cempra Oral Solithromycin in Community-Acquired Bacterial Pneumonia 108
Appendix 110
Methodology 110
Coverage 110
Secondary Research 110
Primary Research 110
Expert Panel Validation 110
Contact Us 110
Disclaimer 111
List of Tables
Number of Products under Development for Community Acquired Pneumonia, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Development by Companies, H2 2016 (Contd..1) 16
Community Acquired Pneumonia - Pipeline by Aridis Pharmaceuticals LLC, H2 2016 17
Community Acquired Pneumonia - Pipeline by BioAegis Therapeutics, Inc., H2 2016 18
Community Acquired Pneumonia - Pipeline by Biotest AG, H2 2016 19
Community Acquired Pneumonia - Pipeline by C10 Pharma AS, H2 2016 20
Community Acquired Pneumonia - Pipeline by InflaRx GmbH, H2 2016 21
Community Acquired Pneumonia - Pipeline by ioGenetics, Inc., H2 2016 22
Community Acquired Pneumonia - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 23
Community Acquired Pneumonia - Pipeline by Lascco SA, H2 2016 24
Community Acquired Pneumonia - Pipeline by Melinta Therapeutics, Inc, H2 2016 25
Community Acquired Pneumonia - Pipeline by Merck & Co., Inc., H2 2016 26
Community Acquired Pneumonia - Pipeline by Nabriva Therapeutics AG, H2 2016 27
Community Acquired Pneumonia - Pipeline by Paratek Pharmaceuticals, Inc., H2 2016 28
Community Acquired Pneumonia - Pipeline by TaiGen Biotechnology Co., Ltd., H2 2016 29
Community Acquired Pneumonia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 30
Community Acquired Pneumonia - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2016 31
Community Acquired Pneumonia - Pipeline by TiGenix NV, H2 2016 32
Assessment by Monotherapy Products, H2 2016 33
Number of Products by Stage and Target, H2 2016 35
Number of Products by Stage and Mechanism of Action, H2 2016 37
Number of Products by Stage and Route of Administration, H2 2016 39
Number of Products by Stage and Molecule Type, H2 2016 41
Community Acquired Pneumonia - Dormant Projects, H2 2016 97
Community Acquired Pneumonia - Discontinued Products, H2 2016 98
List of Figures
Number of Products under Development for Community Acquired Pneumonia, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Products, H2 2016 14
Assessment by Monotherapy Products, H2 2016 33
Number of Products by Targets, H2 2016 34
Number of Products by Stage and Targets, H2 2016 34
Number of Products by Mechanism of Actions, H2 2016 36
Number of Products by Stage and Mechanism of Actions, H2 2016 36
Number of Products by Routes of Administration, H2 2016 38
Number of Products by Stage and Routes of Administration, H2 2016 38
Number of Products by Molecule Types, H2 2016 40
Number of Products by Stage and Top 10 Molecule Types, H2 2016 40
